Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy for Unilateral Retinoblastoma
NCT00335738Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 2005
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 5
01
Overview
Phase 3, open-label trial of vincristine sulfate liposome injection, carboplatin and etoposide in retinoblastoma (Rb) (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-free Survival at 2 years and Overall Survival at 2 years. Started Dec 2005; status: completed.
02
Drugs
vincristine sulfate liposome injectioncarboplatinetoposide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00335738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335738.